Molecular Staging of Cancer

From the contents: The urokinase receptor (uPAR, CD87) as a target for tumor therapy.- Molecular regulation of urokinase receptor (u-PAR) gene expression as one potential concept for molecular staging and therapy.- Stromal cell involvement in cancer.- Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.- Molecular mechanisms of  carcinogenesis in gastric cancer.- Clinical implications of molecular diagnosis in HNPCC.- Minimal residual disease in gastric cancer.- Minimal residual disease in breast cancer and gynecological malignancies.-  Clinical implications of the EGF-receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options.- Minimal residual disease in the bone marrow and peripheral blood of patients with metastatic breast cancer.- Estrogen receptor (ER) expression profile of disseminated epithelial tumor cells in the bone marrow of breast cancer patients.- Detection of circulating tumor cells in blood using an optimized density gradient centrifugation.- Antitumoral and antimetastatic effects of continuous particle mediated cytokine gene therapy.- Genetic subtyping of renal cell carcinoma by comparative genomic hybridization.- Telomere length and hTERT expression in patients with colorectal carcinoma.- Evaluation of the level of bFGF, VEGF, sICAM-1, sVCAM-1 in the serum of patients with thyroid cancer.